

Resource Summary Report

Generated by [dkNET](#) on Aug 30, 2026

Rictor (53A2) Rabbit mAb

RRID:AB_2179963

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2114, RRID:AB_2179963

Antibody Information

URL: http://antibodyregistry.org/AB_2179963

Proper Citation: Cell Signaling Technology Cat# 2114, RRID:AB_2179963

Target Antigen: Rictor (53A2) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W. Consolidation on 11/2018: AB_10694641, AB_10827895, AB_2179963.

Antibody Name: Rictor (53A2) Rabbit mAb

Description: This monoclonal targets Rictor (53A2) Rabbit mAb

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_2179963

Vendor: Cell Signaling Technology

Catalog Number: 2114

Record Creation Time: 20250820T035352+0000

Record Last Update: 20250820T172850+0000

Ratings and Alerts

No rating or validation information has been found for Rictor (53A2) Rabbit mAb.

No alerts have been found for Rictor (53A2) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kadam R, et al. (2026) Optineurin modulates mTORC2/AKT/STAT3 signaling to control MHC class II expression and adaptive immunity against HSV-1. *Cell reports*, 45(4), 117263.

Lane AR, et al. (2026) Distinct signaling mechanisms and proteome phenotypes are elicited by compartment-specific genetic defects of copper homeostasis. *bioRxiv : the preprint server for biology*.

Novoa E, et al. (2026) Lack of PCK1 in hepatic stellate cells causes liver fibrosis by fueling tricarboxylic acid cycle and increasing glycolysis. *Cell metabolism*, 38(4), 729.

Chien JY, et al. (2026) Nostoc commune Extract Attenuates Oxidative Stress and Neuroinflammation in Ischemic Optic Neuropathy Through PI3K/AKT/mTOR Signaling. *Antioxidants (Basel, Switzerland)*, 15(5).

Shao N, et al. (2025) USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation. *Nature communications*, 16(1), 1313.

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. *Cancer research communications*, 5(3), 458.

Lane AR, et al. (2025) Adaptive protein synthesis in genetic models of copper deficiency and childhood neurodegeneration. *Molecular biology of the cell*, 36(3), ar33.

Lanz M, et al. (2025) mTORC2 Regulates Actin Polymerization in Auditory Cells. *Journal of neurochemistry*, 169(2), e70012.

Koshizuka K, et al. (2025) Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer. *Cancer research*, 85(16), 3032.

Koundouros N, et al. (2025) Direct sensing of dietary ω -6 linoleic acid through FABP5-mTORC1 signaling. *Science (New York, N.Y.)*, 387(6739), eadm9805.

Lane AR, et al. (2024) Adaptive protein synthesis in genetic models of copper deficiency and childhood neurodegeneration. *bioRxiv : the preprint server for biology*.

Kim H, et al. (2024) MTOR modulation induces selective perturbations in histone methylation which influence the anti-proliferative effects of mTOR inhibitors. *iScience*, 27(3), 109188.

Rosenlehner T, et al. (2024) Reciprocal regulation of mTORC1 signaling and ribosomal biosynthesis determines cell cycle progression in activated T cells. *Science signaling*, 17(859), eadi8753.

Kim D, et al. (2024) Inhibitory co-receptor Lag3 supports Foxp3⁺ regulatory T cell function by restraining Myc-dependent metabolic programming. *Immunity*, 57(11), 2634.

Dhaliwal NK, et al. (2024) Synergistic hyperactivation of both mTORC1 and mTORC2 underlies the neural abnormalities of PTEN-deficient human neurons and cortical organoids. *Cell reports*, 43(5), 114173.

Ali Y, et al. (2024) mTOR Regulates Mineralocorticoid Receptor Transcriptional Activity by ULK1-Dependent and -Independent Mechanisms. *Endocrinology*, 165(4).

Cao Y, et al. (2023) Enhanced bypass of PD-L1 translation reduces the therapeutic response to mTOR kinase inhibitors. *Cell reports*, 42(7), 112764.

Ali Y, et al. (2022) Mammalian Target of Rapamycin Inhibition Decreases Angiotensin II-Induced Steroidogenesis in HAC15 Human Adrenocortical Carcinoma Cells. *Endocrinology*, 164(1).

Helfenberger KE, et al. (2022) Angiotensin II Regulates Mitochondrial mTOR Pathway Activity Dependent on Acyl-CoA Synthetase 4 in Adrenocortical Cells. *Endocrinology*, 163(12).

Shen Y, et al. (2022) Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension. *Science signaling*, 15(763), eabn2743.